Antithrombotic treatment beyond one year after percutaneous coronary intervention in patients with atrial fibrillation.
Thomas JensenPernille Gro ThraneKevin Kris Warnakula OlesenMorten WürtzMartin Bødtker MortensenChristine GyldenkerneTroels ThimBjarne Linde NørgaardJesper Møller JensenSteen Dalby KristensenJens Cosedis NielsenJohn William EikelboomMichael MængPublished in: European heart journal. Cardiovascular pharmacotherapy (2022)
Our results support long-term OAC monotherapy beyond 1 year after PCI in patients with atrial fibrillation and suggest that DOAC monotherapy is as safe and effective as VKA monotherapy.
Keyphrases
- combination therapy
- percutaneous coronary intervention
- open label
- st segment elevation myocardial infarction
- acute myocardial infarction
- acute coronary syndrome
- coronary artery disease
- atrial fibrillation
- st elevation myocardial infarction
- antiplatelet therapy
- coronary artery bypass grafting
- direct oral anticoagulants
- clinical trial
- replacement therapy